Miyata Junya
   Department   Kawasaki University of Medical Welfare  ,
   Position   Instructor
Article types 原著
Language English
Peer review Peer reviewed
Title Dosimetric comparison of pencil beam scanning proton therapy with or without multi-leaf collimator versus volumetric-modulated arc therapy for treatment of malignant glioma.
Journal Formal name：Medical dosimetry : official journal of the American Association of Medical Dosimetrists
Abbreviation：Med Dosim
ISSN code：18734022/18734022
Domestic / ForeginForegin
Author and coauthor Junya Miyata, Yuki Tominaga, Kazuto Kondo, Yasuaki Sonoda, Hideki Hanazawa, Mami Sakai, Satoshi Itasaka, Masataka Oita, Masahiro Kuroda
Publication date 2023/03
Summary This study aimed to examine the dosimetric effect of intensity-modulated proton therapy (IMPT) with a multi-leaf collimator (MLC) in treating malignant glioma. We compared the dose distribution of IMPT with or without MLC (IMPTMLC+ or IMPTMLC-, respectively) using pencil beam scanning and volumetric-modulated arc therapy (VMAT) in simultaneous integrated boost (SIB) plans for 16 patients with malignant gliomas. High- and low-risk target volumes were assessed using D2%, V90%, V95%, homogeneity index (HI), and conformity index (CI). Organs at risk (OARs) were evaluated using the average dose (Dmean) and D2%. Furthermore, the dose to the normal brain was evaluated using from V5Gy to V40Gy at 5 Gy intervals. There were no significant differences among all techniques regarding V90%, V95%, and CI for the targets. HI and D2% for IMPTMLC+ and IMPTMLC- were significantly superior to those for VMAT (p < 0.01). The Dmean and D2% of all OARs for IMPTMLC+ were equivalent or superior to those of other techniques. Regarding the normal brain, there was no significant difference in V40Gy among all techniques whereas V5Gy to V35Gy in IMPTMLC+ were significantly smaller than those in IMPTMLC- (with differences ranging from 0.45% to 4.80%, p < 0.05) and VMAT (with differences ranging from 6.85% to 57.94%, p < 0.01). IMPTMLC+ could reduce the dose to OARs, while maintaining target coverage compared to IMPTMLC- and VMAT in treating malignant glioma.
DOI 10.1016/j.meddos.2023.01.008
PMID 36914455